Multidrug Resistance Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen
DiscussionSMA-TB will provide proof of concept of the HDT as a co-adjuvant treatment and identify the suitability of the intervention for different population groups (different epidemiological settings and drug susceptibility) in the reduction of tissue damage and risk of bad outcomes for TB patients. This regimen potentially will be more effective and targeted: organ saving, reducing tissue damage and thereby decreasing the length of treatment and sequelae, increasing cure rates and pathogen clearance and decreasing transmission rates. It will result in better clinical practice, care management and increased well-being of...
Source: Trials - June 28, 2023 Category: Research Source Type: clinical trials

Phase 3 Studies of Pfizer ’s Novel Antibiotic Combination Aztreonam-Avibactam (ATM-AVI) Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone NEW YORK--(BUSINESS WIRE) June 01, 2023 --... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 1, 2023 Category: Pharmaceuticals Source Type: clinical trials

Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic Methods
Conditions: Tuberculosis, Multidrug-Resistant; HIV Interventions: Drug: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months); Drug: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months); Drug: Bdq, Lzd, Lfx, Z, Dlm (9-12 months) Sponsors: Harvard Medical School (HMS and HSDM); National Institutes of Health (NIH); Partners in Health; Socios En Salud Sucursal, Peru Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2023 Category: Research Source Type: clinical trials